IP Library Granted Patent US 11,434,535
Granted Patent B2
US 11,434,535 · App. 15/312,138 · Granted Sep 6, 2022

Centromere/kinetochore protein genes for cancer diagnosis, prognosis and treatment selection

Inventors: Weiguo Zhang (Berkeley, CA); Gary Karpen (El Cerrito, CA); Jian-Hua Mao (Moraga, CA)
Assignee: The Regents of the University of California
C12Q1/6886G01N33/57484C12Q2600/106C12Q2600/118C12Q2600/158G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,434,535
App. No.
15/312,138
Granted
Sep 6, 2022
Kind
B2
Abstract

The invention described in the application relates to a panel of gene expression markers for patient with a tumor. The invention thus provides methods and compositions, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to evaluate the likelihood of disease progression or response to chemotherapy or radiation therapy. Such information can be used in determining prognosis and treatment options for cancer patients.

Claims (7)

1. A microarray for detecting expression of a gene panel for predicting likelihood of cancer progression in a patient, wherein the microarray consists of: CENP-A, HJURP, M1S18B, CENP-N, CENP-M, CENP-W, CENP-U, CENP-L, CENP-K, ZWINT, NDC80, NUF2, SPC24, and SPC25; and wherein the probes are immobilized by covalent bonds to a solid support, and each probe is 15 to 80 nucleotides in length.

2. A hybridization assay composition comprising the microarray of claim 1 and an RNA sample obtained sample from a tumor from a patient that has cancer; or a cDNA obtained from RNA from the tumor.

3. The hybridization assay of claim 2 , wherein the the tumor is from early stage breast cancer, an early stage non-small cell lung cancer, or an early stage ovarian cancer.

4. The hybridization assay of claim 3 , wherein the breast cancer is luminal A.

5. The hybridization assay of claim 3 , wherein the breast cancer is luminal B.

6. The hybridization assay of claim 3 , wherein the breast cancer is breast cancer is ER positive breast cancer.

7. A kit comprising amplification primers and probes, wherein the amplification primers and probes consist of amplification primers and probes that are specific for amplifying and detecting expression of a gene panel consisting of: CENP-A, HJURP, M1S18B, CENP-N, CENP-M, CENP-W, CENP-U, CENP-L, CENP-K, ZWINT, NDC80, NUF2, SPC24, and SPC25; and wherein the amplification primers or probes, or both the amplification primers and probes, are attached to a detectable label that is a radioisotope, a fluorophore, a chemiluminescent agent, or an enzyme.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2017
From: ZHANG, WEIGUO; MAO, JIAN-HUA; KARPEN, GARY
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 042956/0084 →
CONFIRMATORY LICENSE Recorded May 17, 2017
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: ENERGY, UNITED STATES DEPARTMENT OF
Reel/Frame 042522/0383 →
Continuity (2)
Provisional Application 61994838 · May 17, 2014
Related Publication 20170175202A1 · Jun 22, 2017